Supplementary data

Supplementary Table S1. Definitions of PsA cases, RA comparator-subjects and comorbidities

Case and comparator definitions					
PsA ¹	ICD10: L40.5, M07.0, M07.1, M07.3				
	ICD9: 696A				
	ICD8: 696.00				
RA	ICD10: M05.0, M05.1, M05.2, M05.3, M05.8, M05.9, M06.0, M06.2, M06.3, M06.8, M06.9, M12.3				
	ICD9: 714A, 714B, 714C, 714W, 719D				
	ICD8: 712.10, 712.20, 712.38, 712.39				
axSpA	ICD10: M45, M460, M461, M468, M469, M072 ¹ , M081				
	ICD9: 720A, 720B, 720C, 720W, 720X				
	ICD8: 712.40, 713.10, 713.11, 713.12, 713.19, 726.99				
Comorbidity definitions – main or secondary diagnoses from any department.					
Depression/anxiety	Prescription within 1 year before baseline, ACT-codes: N06A, N05AN				
Diabetes	Diagnosis within 5 years before baseline, ICD10-codes: E10-E14, O24				
	Prescription of anti-diabetics within 1 year before baseline, ACT-code: A10				
Cancer	Diagnosis within 5 years before baseline, ICD10-codes: Any tumor: C00-C75,				
	Metastic solid tumor: C76-80, Lymphoma: C81-C85, C88, C90, C96, Leukemia: C91-C95				
Congestive heart disease	Diagnosis within 5 years before baseline, ICD10-codes: I11.0, I13.0, I13.2, I50				
Chronic lung disease	Diagnosis within 5 years before baseline, ICD10-codes: J41-J44, J84.1, J84.9				
Myocardial infarction	Diagnosis within 5 years before baseline, ICD10-codes: I20.0, I21, I22				
 M072 was not included in the PsA case definition, but actively excluded to avoid PsA patients with a dominant axial phenotype. 					


Supplementary Table S2. Comparison of matched and non-matched PsA cases (= the PsA cases for whom no suitable RA match could be found).

Baseline	PsA matched	PsA non-matched	
	N=3642	N=283	
Index year, median	2015	2016	
Age, mean (sd)	54.2 (14.1)	35.9 (10.1)	
Sex, N (%) men	1813 (50)	277 (98)	
Days from first PsA/RA diagnosis to start			
of methotrexate, median (IQR)	5 (46)	6 (63)	
Education			
<10, N (%)	704 (19)	33 (12)	
10 to 12, N (%)	1890 (52)	153 (54)	
>12, N (%)	1040 (29)	87 (31)	
Diabetes, N (%)	255 (7.0)	9 (3.2))	
Chronic lung disease, N (%)	50 (1.4)	1 (0.4)	
Myocardial infarction, N (%)	58 (1.6)	0	
Cancer, N (%)	178 (4.9)	0	
Congestive heart disease, N (%)	7 (0.2)	1 (0.4)	
Depression/anxiety, N (%)	562 (15.4)	30 (10.6)	
DAS28-CRP, mean (sd)	4.2 (1.3)	3.9 (0.9)	
DAS28, mean (sd)	4.1 (1.1)	3.9 (1.1)	
Patient-reported pain, mean (sd)	53 (23)	50 (21)	
Patient-reported global health, mean (sd)	51 (24)	51 (20)	
Evaluator's assessment of disease activity			
Remission, N (%)	7 (1)	0	
Low, N (%)	221 (19)	18 (19)	
Moderate, N (%)	720 (63)	66 (69)	
High, N (%)	195 (17)	12 (13)	
Maximal, N(%)	7 (1)	0	
CRP, median (IQR)	7 (15)	10 (18)	
Swollen 28-joint count, mean (sd)	4.2 (4.3)	3.2 (3.1)	
Tender 28-joint count, mean (sd)	5.3 (5.1)	4.3 (3.8)	

Supplementary Table S3. Probability of not having started another DMARD and not having stopped methotrexate therapy, at one and two years after methotrexate initiation, calculated by taking censoring into account (i.e. survival distribution estimates). Numbers of patients included in the analyses, PsA/RA: 3642/3642.

		Survival distribution estimates (95%CI)		
		At one year after start of methotrexate	At two years after start of methotrexate	
Not having started any other DMARD	PsA	0.76 (0.75-0.78)	0.66 (0.65-0.68)	
	RA	0.72 (0.71-0.74)	0.60 (0.59-0.62)	
Not having started specifically a b/tsDMARD	PsA	0.85 (0.84-0.86)	0.77 (0.75-0.78)	
	RA	0.84 (0.83-0.85)	0.74 (0.73-0.76)	
Not having stopped methotrexate	PsA	0.87 (0.86-0.88)	0.71 (0.70-0.73)	
	RA	0.90 (0.89-0.91)	0.76 (0.74-0.77)	

Supplementary Figure S1. Follow-up stratified by calendar time at median start year (2015) for methotrexate.



Time to starting any other DMARD Time to starting a b/tsDMARD Time to discontinuing methotrexate

Supplementary Table S4. Comparison of baseline characteristics of the subsets of patients included in the response analyses and the whole cohort.

	All matched cases/comparator- subjects		Only PsA/RA with a MTX start date and baseline visit in SRQ	
Baseline	PsA=3642	RA=3642	PsA=1174	RA=2135
Index year, median	2015	2015	2016	2015
Age, mean (sd)	54.2 (14.1)	54.5 (14.4)	53.7 (14.1)	54.4 (14.5)
Sex, N (%) men	1813 (50)	1813 (50)	598 (51)	1065 (50)
Days from first	5 (46)	1 (15)	3 (37)	1 (12)
PsA/RA diagnosis				
to start of				
methotrexate,				
median (IQR) Education				
	704 (10)	027 (22)	200 (10)	477 (22)
<10, N (%)	704 (19)	837 (23)	209 (18)	477 (22)
10 to 12, N (%)	1890 (52)	1765 (48)	596 (51)	1033 (48)
>12,N (%)	1040 (29)	1025 (28)	367 (31)	621 (29)
missing, N	8 (0)	15 (0)	2 (0)	4 (0)
Diabetes, N (%)	255 (7.0)	265 (7.3)	77 (6.6)	132 (6.2)
Chronic lung	50 (1.4)	78 (2.1)	16 (1.4)	38 (1.8)
disease, N (%)				
Myocardial	58 (1.6)	59 (1.6)	18 (1.5)	36 (1.7)
infarction, N (%)				
Cancer, N (%)	178 (4.9)	178 (4.9)	58 (4.9)	103 (4.8)
Congestive heart	7 (0.2)	9 (0.3)	1 (0.1)	5 (0.2)
disease, N (%)				
Depression, N (%)	562 (15.4)	441 (12.1)	185 (15.8)	243 (11.4)